eligibility_summary
Inclusion: Adults ≥18, ECOG 0–2, confirmed MM, transplant‑eligible and not MRD‑negative CR after high‑dose chemo, adequate counts/organ function (e.g., bilirubin ≤1.5×ULN, eGFR ≥30), limited proteinuria, WOCBP contraception/negative test, prior tox ≤G1, consent. Exclusion: recent bleeding/surgery/plasmapheresis, corneal disease/contact lenses, active infection (HIV/HBV/HCV), major cardiac/liver/renal disease, other active malignancy/unstable illness, poor vision, recent investigational/mAb use, prior belantamab progression, pregnancy, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm consolidation in MRD-positive multiple myeloma post–autologous transplant tests: 1) Belantamab mafodotin (biologic antibody–drug conjugate): an anti-BCMA monoclonal antibody linked to the microtubule inhibitor MMAF. Mechanism: binds BCMA on malignant plasma cells, internalizes, delivers MMAF to disrupt microtubules and induce cell death (with potential Fc-mediated cytotoxicity). 2) Lenalidomide (small-molecule immunomodulatory drug, IMiD). Mechanism: binds cereblon E3 ligase, promotes IKZF1/IKZF3 degradation, enhancing T/NK-cell activity, anti-angiogenesis, and direct anti-myeloma effects. Targets/pathways: BCMA-expressing plasma cells, microtubules, CRBN–IKZF axis, immune effector activation and myeloma microenvironment. Regimen: belantamab IV day 1 every 8 weeks ×6, lenalidomide PO days 1–28 each cycle.